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Summary Analogues of luteinising hormone releasing hormone (LHRH) have recently been introduced as an
alternative to surgical orchidectomy in prostate cancer, but there has been concern about the economic costs
of long-term treatment. The paper presents a comparison of costs for LHRH analogues versus orchidectomy
in patients with advanced prostate cancer. The cost for the surgical procedure was estimated using data on
patients treated with orchidectomy in Stockholm County, Sweden, during 1981-86. Estimates of costs for
treatment with a depot LHRH analogue was based on observed treatment times among patients with
symptomatic prostate cancer in a British randomised clinical trial of medical castration versus surgical
orchidectomy. The average cost for orchidectomy was estimated at £2,580 i.e. 7-31% less than for treatment
with a depot LHRH analogue (£2,760-£3,380) assuming a mean treatment time in the range 19-23 months.
The most cost-effective policy for castration was found to be initial treatment with an LHRH analogue
followed by deferred orchidectomy after about 2 years among long-term responders. This policy would obviate
the need for surgery in about 85% of the patients and the average cost (£1,900) would be about 26% lower
compared to that of a policy of primary orchidectomy in all patients.
Long-term treatment with analogues of luteinizing hormone
releasing hormone (LHRH) decreases the blood levels of
pituitary gonadotrophins which results in a 'medical' castra-
tion. The long-term hormonal effects - which are reversible -
are the same as those obtained with oophorectomy in young
women or orchidectomy in males (Chodak, 1989). LHRH
analogues have recently become commercially available. They
have been introduced as an alternative to the mentioned
ablative, surgical procedures in premenopausal breast cancer
and prostate cancer. However, there has been concern about
the economic costs which have been described as high in
comparison with surgical castration.
This paper presents a comparison of costs for the two
methods of castration in patients with advanced prostate
cancer. The estimated average cost for orchidectomy was
based on data on patients who received such treatment dur-
ing 1981-86 in Stockholm County, Sweden. We also esti-
mated the average cost of a policy of combining initial
LHRH analogue treatment with deferred orchidectomy in
long-term responders. Theoretically, this approach might be
the most cost-effective policy for castration in advanced pros-
tate cancer since it might obviate the need for surgery in
many patients. The analysis was intended only to include
costs that are different for surgery compared to medical
treatment. Costs for e.g. the clinical follow-up and diagnostic
examinations were thus not included because it seemed
reasonable to assume that they would be the same irrespec-
tive of the type of castration.
Material and methods
The average cost ofsurgical orchidectomy
Was estimated using official data on the average duration of
the hospital stay in connection with the orchidectomy and
the average daily cost according to the Stockholm County
Council. Most patients with prostate cancer are old. Conse-
quently, orchidectomy is seldom performed on an out-patient
basis. Data on the length of the hospital stay for patients
treated in Stockholm County, Sweden (population 1.6 mil-
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lion) during 1981-86 was obtained from the Stockholm
County Council computerised register of in-patient hospital
care (Personal communication, A Leimanis, HSN/GEMI,
Stockholm County Council, 1990). At the time of this ana-
lysis, computerised data on admissions after 1986 were not
available. The register covers about 95% of all hospital
admissions in the county. Non-notification to the register
mainly concerns admissions into long-stay centers with a
geriatric profile (Personal communication, P.-O. Buren, Min-
istry of Health and Social Affairs, Stockholm, 1989).
According to the register, 2,061 patients underwent bilat-
eral orchidectomy because of prostate cancer during the
studied period: 475 patients (23%) were treated at depart-
ments of general surgery and 1,586 (75%) at departments of
urology; 1,673 patients (81%) underwent orchidectomy alone
during their hospital stay, i.e. no other diagnostic or thera-
peutic procedure (e.g. electroresection) was done. In addition
to the hospital stay, it was considered reasonable to assume
that surgical castration requires two out-patient visits: one
pre- and one postoperatively.
All health care in Stockholm County for patients covered
by the Swedish National Health Insurance is funded by the
County Council. Each year the Council calculates the actual
average daily cost per in-patient at different types of depart-
ments as well as the cost of out-patient visits (Personal
communication, K. Nordkvist, HSN-staben, Stockholm
County Council, 1990). These figures include all costs asso-
ciated with the hospital stay or visit, e.g. surgery, intensive
care, X-ray examinations, blood tests, doctors' fees, etc. This
implies that they may underestimate the actual daily cost for
a patient who, for instance, undergoes several complicated
surgical procedures and who spends a long time postop-
eratively in an intensive care unit, and may overestimate the
actual costs for a patient who, for instance, is only admitted
for observation and nursing care. For the purposes of this
study it was assumed that the County Council estimates
represented reasonable estimates of the actual average daily
costs for patients with advanced prostate cancer treated with
an orchidectomy.
Average cost oftreatment with LHRH analogues
Currently available LHRH analogues are administered as
daily subcutaneous injections, monthly depot injections, or as
nasal spray. The depot injections can be given by a district
nurse or by the responsible clinician during routine follow-up
visits. Daily injections imply - in practice - self-administra-
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tion. According to the 1990 Swedish prices the monthly drug
cost for LHRH analogue treatment is £132 for daily injec-
tions or monthly depots, and £150 for nasal spray
(£1 = 10.50 Swedish crowns). With the depot preparations
the cost of a monthly visit to a district nurse (£20) should be
added to the total cost for the treatment.
The cost of treatment with LHRH analogues is directly
related to the total treatment time. According to the litera-
ture the median time to disease progression - based on
actuarial estimates - during endocrine therapy of advanced,
symptomatic prostate cancer varies between 7-24 months
(Smith et al., 1986; Pavone-Macaluso et al., 1986; Benson &
Gill, 1986). However, the actual median treatment time is
shorter because many patients die because of intercurrent
causes during follow-up (and are therefore censored in
actuarial calculations of time to disease progression). On the
other hand the mean time to disease progression may be
considerably longer than the median time because a small
proportion of patients may respond to treatment for several
years.
We obtained data on the actual time to discontinuation of
treatment (because of death or disease progression) among
patients with advanced prostate cancer who were included in
a British randomised clinical trial of LHRH analogue treat-
ment versus surgical orchidectomy (Peeling, 1989). The med-
ian follow-up time was 14 months (range: 1-27 months). In
that study 122 of the 148 patients treated with a depot
LHRH analogue (82%) had died or discontinued the treat-
ment before the last date of follow-up. The remaining 26
patients were still on treatment. For the purposes of this
analysis we assumed a mean treatment time of 3 or 5 years in
that subgroup. This implied a mean treatment time for all
patients allocated to the depot LHRH analogue of 19.0
months and 23.2 months respectively.
It may be argued that patients might benefit from con-
tinued treatment with an LHRH analogue despite evidence
of progressive disease. However, to our knowledge, there are
no clinical data to support that hypothesis.
Average cost ofcombining LHRH analogues with
orchidectomy
Many patients with advanced prostate cancer die a short
time after diagnosis because of progressive cancer or inter-
current disease. It might be cheaper to treat such patients
with an LHRH analogue than to do an orchidectomy
because of the short treatment time. On the other hand, some
patients respond to endocrine treatment for several years. In
such patients an orchidectomy might be cheaper. At diag-
nosis it is difficult to determine which patients will become
long-term responders. Therefore, it is possible that the most
cost-effective policy is to treat all patients initially with an
LHRH analogue and to do an orchidectomy only on those
who turn out to be long-term responders. To study this
hypothesis we calculated the average cost per patient of a
policy of initial LHRH analogue treatment followed by
orchidectomy at 3, 6, 12, 24 or 36 months. In the mentioned
randomised trial the respective percentage of patients still
alive without evidence of progressive disease at 3, 6, 12 and
24 months was 75, 54, 35 and 14. Due to short follow-up a
corresponding figure at 36 months was unavailable. For the
purposes of this study we assumed that it was 14%.
Results
Average cost of surgical orchidectomy
The average length of the hospital stay for orchidectomy
patients in Stockholm county during 1981-1986 was 10.3
days (range: 8.5-14.0 days) at the departments of surgery
and 8.3 days (range: 7.5-10.0 days) at the departments of
urology (Table I). The average stay for those patients who
underwent orchidectomy alone was 7.4 days: 8.2 days at
departments of surgery and 7.1 days at departments of
Table 1 Average hospital stay for orchidectomy patients treated at
departments ofgeneral surgery orurology in Stockholm countyduring
1981-1986
Type ofpatient
anddepartment
1981-82 1983-86
Average stay (days)
1981-86
All patients:
-dpts ofgeneral surgery 12.3 9.4 10.3
-dpts ofurology 8.8 7.7 7.8
Patients treated with
orchidectomy alone:
-dpts ofgeneral surgery 10.2 7.3 8.2
-dpts ofurology 8.0 6.8 7.1
The average stay for patients who were treated with orchidectomy
alone are shown separately.
urology. The average stay was slightly shorter during
1983-86 (7.8 days) than during 1981-82 (9.1 days).
According to the Stockholm County Council figures for
1990 the average daily cost for in-patients was £311 (range:
£243-£333) at the departments of general surgery and £290
(£262-£345) at the departments ofurology. The average cost
for out-patient visits was £104 at the departments of general
surgery and £109 at the departments of urology. The average
cost for a surgical orchidectomy was thus calculated as the
sum of an 8-day hospital stay (£2,360) and two out-patient
visits (£216) i.e. a total of about £2,580.
Average cost ofLHRH analogue treatment
A mean treatment period of 19.0 or 23.2 months and a
monthly drug cost of £132 implies an average drug cost of
£2,510-£3,060. To this should be added the cost ofvisits to a
district nurse for administration of the drug when it is not
given by the responsible clinician during routine follow-up
visits (with 3 month intervals). The average total cost for the
treatment can thus be estimated at £2,760-£3,380 i.e. 7-31%
more than the mentioned average cost of an orchidectomy.
Average cost ofcombined treatment
The cost of LHRH analogue treatment is directly related to
the treatment period. The cost among long-term responders
may thus become very high (Table II). Table III shows the
average cost per patient of a policy of initial LHRH ana-
logue treatment followed by orchidectomy after 3, 6, 12, 24
or 36 months. An initial LHRH analogue treatment period
of about 2 years would result in an average cost that is 26%
lower compared to that of initial orchidectomy in all patients
(£1,900 versus £2,580). Moreover, surgery would be avoided
in about 85% of the patients.
Discussion
Orchidectomy and treatment with LHRH analogues differ in
respect to endocrine effects, side-effects and economic costs.
There have been reports suggesting a direct effect of LHRH
analogues on tumour cells, but in advanced prostate cancer
this effect has not been shown to be clinically relevant
(Chodak, 1989). The transient early increase of gonado-
trophins after initiation of LHRH analogue therapy has been
suggested to precipitate a 'flare' reaction in a small percen-
tage of patients. Such an effect has not been reported follow-
ing orchidectomy. On the other hand, orchidectomy may be
associated with surgical complications, e.g. wound infections
or thrombosis. Because of the lack of reliable data costs
associated with such complications were not included in this
analysis so the average cost for orchidectomy may have been
slightly underestimated. LHRH analogues are not associated
with any surgical trauma, they have a reversible endocrine
effect and may therefore be more acceptable to the patient.
In summary, there are advantages and disadvantages with
both orchidectomy and LHRH analogues. In such a case theLHRH ANALOGUES VERSUS ORCHIDECTOMY 929
Table II Estimated average cost for castration as a function of the
duration of the hospital stay in connection with orchidectomy or the
duration of treatment with an LHRH analogue
Orchidectomy LHRH analogue treatment
Duration of Duration of
hospital stay treatment
(days) Cost (£) (months) Cost (£)
3 1,100 3 440
4 1,400 6 880
5 1,690 9 1,320
6 1,990 12 1,760
7 2,280 18 2,640
8 2,580 24 3,520
9 2,870 36 5,280
Table III Estimated average cost for a surgical orchidectomy,
treatment with a depot LHRH analogue, or a combination of initial
LHRH analogue treatment followed by deferred orchidectomy among
long-term responders
Treated with
Policyfor castration surgery, % Average cost (f)
Surgical orchidectomy 100 2,580
LHRH analogue 0 2,760-3,380a
LHRH analogue followed
by orchidectomy at:
- 3 months 75 2,380
- 6 months 54 2,120
- 12 months 35 1,990
- 24 months 14 1,900
- 36 months 14 2,290
aMean treatment time in the range 19.0-23.3 months.
preference of the patient is particularly important and a
majority seem to prefer LHRH analogues (Cassileth et al.,
1989). In this paper we have estimated the difference in
economic costs for the two alternatives. Economic considera-
tions may be important for the individual patient as well as
for society.
It is difficult to reliably compare costs for therapies that
are inherently different, e.g. surgery versus medical treatment.
For instance, our estimates of the cost for orchidectomy
could be criticised because calculations based on official data
on the average length of the hospital stay and the average
daily cost may not result in an accurate estimate of the actual
cost for a surgical orchidectomy. At present there is no
widely accepted standard method to calculate such a cost.
However, for comparative purposes it is interesting to note
that according to the American DRG-system (Diagnosis
Related Groups) the cost for a surgical orchidectomy is
$3,200 excluding doctors' fees, i.e. the total cost would be
about the same as our estimate (£2,580).
We found that the average cost of a surgical orchidectomy
was 7-31% lower than the average cost for treatment with a
depot LHRH analogue (£2,580 versus £2,760-£3,380). How-
ever, the most-cost effective policy for castration was initial
LHRH analogue treatment combined with deferred orchidec-
tomy after about 2 years. This approach would decrease the
number of surgically treated patients who do not benefit
from the treatment because of early progression or intercur-
rent death and would decrease the cost of the LHRH
analogue among patients who become very long-term res-
ponders. The average cost was found to be 26% lower
compared to a policy of initial surgical orchidectomy in all
patients.
It could be argued that the in-hospital stay need not be as
long as 7-9 days, i.e. the average length of in-hospital care
in Stockholm county during 1981-1986. Theoretically, orchi-
dectomy patients could be admitted on the first day, have
surgery on the second, and be discharged on the third day.
Such a routine would naturally result in a considerably lower
cost (Table II). However, calculations based on a fixed
average daily cost may overestimate the effect of shortening
the in-hospital period. In reality the daily cost is the highest
during the first days of the stay - i.e. during the day of
surgery and the immediate postoperative period - and lower
toward the end of the stay when the patient only receives
nursing care. The figures used in our calculations represented
the actual mean in-hospital period, not how long the in-
hospital period ought to be in an ideal situation. Only 25%
of the patients who were treated with an orchidectomy in
Stockholm during 1981-86 were discharged on the first post-
operative day. This observation is not surprising in view of
the high mean age ofthe patients (74 years) and their serious
disease.
A more extensive use of LHRH analogues instead of
orchidectomy would result in fewer beds at departments of
surgery and urology being occupied by orchidectomy pa-
tients. By extrapolating the mentioned figures for Stockholm
county it can be estimated that about 40 surgical beds in
Sweden (population 8.5 million) are constantly being
occupied by orchidectomy patients.
References
BENSON, R.C. & GILL, G.M. (1986). Estramustine phosphate com-
pared with diethylstilbestrol. A randomized, double-blind, cross-
over trial for stage D prostate cancer. Am. J. Clin. Oncol., (CCT)
9, 341.
CASSILETH, B.R., SEIDMON, E.J., SOLOWAY, M.S. & 4 others (1989).
Patients' choice of treatment in stage D prostate cancer. Urology,
23 (Suppl), 57.
CHODAK, G.W. (1989). Luteinizing hormone-releasing hormone
(LHRH) agonists for treatment of advanced prostatic carcinoma.
Urology, 33 (Suppl), 42.
PAVONE-MACALUSO, M., DE VOOGT, H., VIGGIANO, G. & 4 others
(1986). Comparison of diethylstilbestrol, cyproterone acetate and
medroxyprogesterone acetate in the treatment of advanced pros-
tatic cancer: final analysis of a randomized phase III trial of the
European Organization for Research on Treatment of Cancer.
Urological Group. J. Urol., 136, 624.
PEELING, W.B. (1989). Phase III studies to compare goserelin (Zol-
adex) with orchidectomy and with diethylstilbestrol in treatment
of prostatic carcinoma. Urology, 33 (Suppl), 45.
SMITH, P.H., SUCIU, S., ROBINSON, G. & 7 others (1986). A com-
parison of the effect of diethylstilbestrol with low dose estramus-
tine phosphate in the treatment of advanced prostatic cancer:
final analysis of a phase III trial of the European Organization
for Research on Treatment of Cancer. J. Urol., 136, 619.